A Study of a New PET Scanner in People With Cancer
Status
RECRUITING
Phase
Age
≥ 18 Years
Enrollments
90Conditions
Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate CancerSummary
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Detailed Description
This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.
Locations
7 locations Found with status Recruiting
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Status
- RECRUITING
Contact Person
- Heiko Schoder, MD
- 212-639-8001
Principal Investigator
- Heiko Schoder, MD
Eligibility Criteria
Inclusion Criteria:
Eligibility Criteria for objective #1:
* Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
* Patients who are undergoing a planned PET-CT scan at main campus of MSK.
* Patients must be ≥ 18 years old
Eligibility Criteria for objective #2:
* Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
* Patients with metastatic prostate or head and neck cancer.
* Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
* Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
* Patients must be ≥ 18 years old
Eligibility Criteria for objective #3:
* Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
* Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK.
* Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
* Patients must be ≥ 18 years old
Exclusion Criteria:
* Patients who suffer from claustrophobia.
* Women who are pregnant or breast-feeding.
* Patients < 18 years of age
Study Plan
Patients with lung, head and neck, and prostate cancer
The only investigational aspect of this quality improvement protocol is the acquisition of additional PET/CT imaging data (e.g. breath-hold, dynamic, and/or delayed acquisition) in patients who are already scheduled to receive a PET/CT scan as part of standard of care or under an existing clinical trial.
DIAGNOSTIC_TEST:
Biograph Vision Quadra scannerDescription:
new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner.DIAGNOSTIC_TEST:
PET/CTDescription:
Scheduled PET/CT scan
Outcome Measures
Primary Outcome Measures
image quality
Timeline
Last Updated
July 8, 2026Start Date
July 8, 2026Today
October 1, 2026Completion Date ( Estimated )
June 1, 2029
Sponsors of this trial
Lead Sponsor
Memorial Sloan Kettering Cancer Center
RECRUITING 
≥ 18 Years